PGXL Vice President of Lab Operations Dr. Kristen Reynolds collaborated on a study intended to help clinical laboratories adopt CYP2D6 genotyping for patients considering tamoxifen therapy.
Published by the American College of Medical Genetics and Genomics in Genetics in Medicine, the focus of the paper is the implementation of testing, including the kind of analytic interpretation PGXL work hard to provide. From the article:
CYP2D6 reports should have an interpretative component, which may include additional recommendations such as use of alternative therapies, altered dosage, avoidance of known CYP2D6 inhibitors, and other confounding clinical factors, if known…The interpretative report should effectively convey the result and its clinical ramifications to a “nonexpert physician.”
That, in a nutshell, is exactly what PGXL does with it’s PerMIT-based interpretive reports — though we’re not comfortable with the phrase “nonexpert physicians.”